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Abstract
The physiological role of F1F0-ATPase inhibition in ischemia may be to retard ATP depletion although views of the
significance of IF1 are at variance. We corroborate here a method for measuring the ex vivo activity of F1F0-ATPase in
perfused rat heart and show that observation of ischemic F1F0-ATPase inhibition in rat heart is critically dependent on the
sample preparation and assay conditions, and that the methods can be applied to assay the ischemic and reperfused human
heart during coronary by-pass surgery. A 5-min period of ischemia inhibited F1F0-ATPase by 20% in both rat and human
myocardium. After a 15-min reperfusion a subsequent 5-min period of ischemia doubled the inhibition in the rat heart but
this potentiation was lost after 120 min of reperfusion. Experiments with isolated rat heart mitochondria showed that ATP
hydrolysis is required for effective inhibition by uncoupling. The concentration of oligomycin for 50% inhibition (I50) for
oxygen consumption was five times higher than its I50 for F1F0-ATPase. Because of the different control strengths of F1F0-
ATPase in oxidative phosphorylation and ATP hydrolysis an inhibition of the F1F0-ATPase activity in ischemia with the
resultant ATP-sparing has an advantage even in an ischemia/reperfusion situation. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Aerobic mitochondria synthesize ATP by utilizing
the proton gradient and membrane potential across
their inner membrane through the mediation of a
reversible H-ATPase/ATP synthase (F1F0-ATPase).
The work of Rouslin [1] ¢rst suggested that mito-
chondrial F1F0-ATPase may also be a major con-
sumer of ATP under ischemic conditions, and this
was later con¢rmed by Jennings and coworkers [2].
F1F0-ATPase is regulated by two inhibitor pro-
teins: calcium-sensitive CaBI and membrane poten-
tial-sensitive IF1. Reversible inhibition by IF1 occurs
upon disappearance of the mitochondrial membrane
potential (for a review of the regulation of F1F0-
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ATPase, see [3]). Divergent views have been ex-
pressed on the signi¢cance of IF1 in the fast-beating
hearts of small rodents such as the rat. Rouslin and
coworkers could not demonstrate any signi¢cant in-
hibition of F1F0-ATPase in rat heart [4^9], whereas
Das and Harris [10] and our group [11] were able to
show an inhibition of F1F0-ATPase during ischemia.
The experiments reported here were carried out to
corroborate the method for measuring the inhibited
state of F1F0-ATPase ex vivo. The e¡ects of sample
storage, pH, isolation method and the behavior of
the F1F0-ATPase during ischemia and reperfusion
were studied in isolated rat hearts, and the method
also enabled us to measure F1F0-ATPase activity in
human hearts subjected to ischemia/reperfusion dur-
ing coronary bypass surgery.
As pointed out previously [2,11,12], inhibition of
F1F0-ATPase may be linked to ischemic precon-
ditioning de¢ned as a protective e¡ect of a short
ischemic bout and reperfusion against cell damage
upon subsequent long lasting ischemia and reper-
fusion. The potential bene¢ts of ischemic inhibi-
tion of F1F0-ATPase, counteracted by potential dis-
advantages during subsequent reperfusion is not
straightforward. Estimates of the control strengths
of F1F0-ATPase for ATP hydrolysis and oxidative
phosphorylation may give information of this sub-
ject.
2. Materials and methods
2.1. Materials
Carbonylcyanide m-chlorophenylhydrazine
(CCCP) and oligomycin were obtained from Sigma
Chemical Co.
2.2. Animals and perfusion methods
This investigation conforms with the Guide for the
Care and Use of Laboratory Animals (NIH Publica-
tion No. 85-23, revised 1985) and was conducted
after prior approval by the Laboratory Animals
Committee of the University of Oulu.
Three-month-old male Sprague^Dawley rats from
the Laboratory Animal Center of the University
of Oulu were used. They were anesthetized with
intraperitoneal sodium pentobarbital (60 mg/kg
body weight), 500 IU heparin was injected into the
inferior vena cava, and 1 min later the hearts were
excised and rinsed in phosphate-free ice-cold
Krebs^Henseleit bicarbonate solution containing
120 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 0.25
mM Ca^EDTA, 1.2 mM MgSO4, 25 mM NaHCO3,
10 mM glucose, and 12 IU/l insulin. The hearts were
perfused with the Krebs^Henseleit medium at a pres-
sure of 90 cmH2O (8.83 kPa) in a modi¢ed Langen-
dor¡ apparatus maintained at 37‡C by means of
water mantles, and the medium was gassed with
O2/CO2 (19:1).
2.3. Experimental protocol for intact rat hearts
After a 15-min normoxic stabilization perfusion
period, the hearts were cut into two slices. One slice
was immediately placed in a self-sealing plastic bag
containing a small amount of Krebs^Henseleit bu¡er
gassed with N2/CO2 (19:1) in order to simulate glob-
al ischemia, while the second slice was immediately
homogenized in 1.5 ml of a solution consisting of
1 mM MgCl2 and 2 mM EGTA, 20 mM MOPS,
pH 6.5, 7.0 or 7.5 (or Hepes, pH 8.0) with an Ultra-
Turrax homogenizer (Janke and Kunkel, Staufen)
for 30 s. The homogenate was sonicated at once or
after storage for 30 or 60 min in an ice-water bath.
The total sonication time was 25 s in 5-s bursts sep-
arated by 7-s intervals in an ice-water bath. This was
the sonication time when the yield of activity reached
a plateau. Longer sonication times did not improve
the yield of enzyme activity. The homogenate was
centrifuged at 5300 rpm in a Heraeus Biofuge for
30 s. The supernatant was diluted with the same bu¡-
er to a protein concentration of 0.5 mg/ml. The other
slice was processed similarly after 20 min of global
ischemia.
The activity of F1F0-ATPase was measured in a
cuvette containing 33 mM Tris acetate, 83 mM su-
crose, 10 mM MgCl2, 1 mM KCN, 1 mM EDTA,
2 mM ATP, 1.5 mM phosphoenolpyruvate, 0.17 mM
NADH, 4 U of pyruvate kinase and 20 U of lactate
dehydrogenase per ml, at the same pH as during
homogenization and sonication. NADH oxidation
was monitored in terms of changes in the absorbance
di¡erence at 340 and 385 nm on a Shimadzu-3000
dual-wavelength spectrophotometer at 22‡C, using
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an absorption coe⁄cient of 5.33 mM31 cm31. The
activity was determined in the absence and presence
of oligomycin (3.9 Wg/ml), and the oligomycin-sensi-
tive portion was denoted as F1F0-ATPase. The activ-
ity was normalized to protein concentration in the
preparation. Protein was measured using the Bio-
Rad assay [13].
To test the e¡ect of high pH and high salt concen-
tration to the inhibition of F1F0-ATPase, a myocar-
dial sample taken after 20 min of global ischemia
was prepared as described above and incubated 10
min at 25‡C either in 1 mM MgCl2, 2 mM EGTA, 20
mM Hepes (pH 7.0 or 9.5) or in 160 mM KCl, 1 mM
MgCl2 and 2 mM EGTA, 20 mM Hepes (pH 7.0)
before F1F0-ATPase assay at pH 7.2.
In addition, the behavior of F1F0-ATPase activity
during ischemia and reperfusion was measured at
various time points as shown in Fig. 4. The hearts
were immediately homogenized in 3 ml of a solution
consisting of 20 mM Hepes, 1 mM MgCl2 and 2 mM
EGTA, pH 7.2. The sample was prepared and the
ATPase activity measured as described above.
2.4. Experiments with isolated mitochondria
Each rat was anesthetized with 60 mg/kg pentobar-
bital. The heart was excised and immediately per-
fused through the aorta with 100 mM KCl, 50 mM
Hepes, 5 mM MgCl2 1 mM EDTA, pH 7.4 (KCl
medium) containing 2 mg/ml Bacillus subtilis alkalase
(Novo) until the e¥uent £uid was clear. The muscle
was chopped into 5 ml of the same medium, incu-
bated for 2 min at 0‡C diluted with 10 ml of protein-
ase-free medium. The £uid was removed and the
mince was homogenized in 10 ml of KCl medium
containing 1 mM ATP and 0.1% defatted bovine
serum albumin. The homogenate was centrifuged at
350Ug for 5 min, 6000Ug for 10 min. The pellet was
resuspended in 40 ml of KCl medium and centri-
fuged at 6000Ug for 10 min. The pellet was resus-
pended in 225 mM mannitol, 75 mM sucrose, 10 mM
Hepes, 1 mM EDTA, pH 7.4.
Mitochondrial oxygen consumption was measured
with a Clark-type oxygen electrode at 25‡C in 200
mM mannitol, 50 mM KCl, 25 mM Hepes, 5 mM
K2HPO4, 1 mM MgCl2 in the presence of 5 mM
glutamate and 5 mM malate. The mitochondria
were incubated for 2 min in the presence of varying
amounts of oligomycin, and state 3 respiration initi-
ated by adding 0.5 mM ADP.
The F1F0-ATPase activity was also measured in
state 4 mitochondria and mitochondria uncoupled
with 2 WM CCCP in the presence of 5 mM ATP.
The e¡ect of 5-min ischemia on F1F0-ATPase
activity in intact Langendor¡-perfused hearts was
also measured in mitochondria isolated from these.
In these experiments the mitochondria were iso-
lated as described in [1]. Brie£y, each rat heart was
cut into the pieces and homogenized with a Potter^
Elvehjem homogenizer in a medium containing
180 mM KCl, 10 mM EGTA, 0.5% BSA and
10 mM MOPS, pH 7.2. The homogenate was then
centrifuged at 450Ug for 10 min. The supernatant
was poured through a cheesecloth and centrifuged
at 10 000Ug for 10 min. The pellet was then
suspended in the isolation medium and the
F1F0-ATPase assay was performed after sonication
as described above.
2.5. Patients
This research was conducted according to the eth-
ical standards as formulated in the Helsinki Declara-
tion of 1975 (revised in 1983) and approved by the
Ethical Committee of the Medical Faculty of Oulu
University, and the patients gave their informed writ-
ten consent before the operation. Nine patients ad-
mitted for elective aortocoronary bypass grafting
were recruited. The exclusion criteria were ejection
fraction below 40%, signi¢cant left main coronary
artery stenosis and unstable angina.
2.6. Operative and cardioplegic techniques
The standardized anesthetic technique described
earlier by Kaukoranta and coworkers [14] was
used. All the operations were performed by the
same experienced cardiac surgeon (M.L). Cardiopul-
monary bypass was established with a single two-
stage atrial cannula and an ascending aortic cannula.
A cardioplegic cannula with venting and pressure
monitoring ports (DLP, Grand Rapids, MI) was
used for initial antegrade delivery of cardioplegic so-
lution. A retrograde coronary sinus catheter with a
manually in£atable balloon (DLP) was positioned
using the closed transatrial technique before initia-
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tion of the full cardiopulmonary bypass. The distal
anastomoses were completed in the order of impor-
tance according to the surgeon’s preference, except
that the left internal mammary artery was anasto-
mosed last. The proximal vein anastomoses were ¢n-
ished before aortic declamping.
An aspartate^glutamate enriched cardioplegic so-
lution [14] was used in both groups. One part of the
solution in seven parts of blood was delivered using a
commercial cardioplegia set (D 720; Dideco). Before
arrest, the heart was subjected to 5 min of global
ischemia by clamping the aorta and keeping the
aortic root pressure at zero by means of continuous
venting. All hearts continued to beat in sinus rhythm
throughout this period, and none started to ¢brillate.
After ischemia, the hearts were arrested by delivering
antegrade normothermic cardioplegia solution with
extra KCl at 300 ml/min for 5 min, keeping the
root pressure below 60 mmHg. Whenever electric
activity reappeared, extra potassium boluses were ad-
ministered into the cardioplegia line. After arrest, the
£ow of cardioplegia solution was switched to retro-
grade mode and continued at a rate of 200 ml/min.
Coronary sinus pressure was monitored continuously
and maintained below 40 mmHg throughout the ret-
rograde cardioplegia. Occasionally the cardioplegia
had to be interrupted for short periods to improve
visibility during construction of the distal anastomo-
ses. The aortic root was vented continuously during
retrograde cardioplegia.
2.7. Myocardial biopsies
Transmural myocardial biopsies for ATPase activ-
ity measurement were taken with a Tru-Cut needle
(William Schmidt, Valencia, CA) from the left ante-
rior myocardium, which was macroscopically normal
in appearance. The ¢rst biopsy was taken before the
aortic cross-clamp, the second at the end of the 5-
min ischemic period and the third after 7 min of
reperfusion (5 min antegrade+2 min retrograde).
The biopsy samples were immediately homogenized
in 1.0 ml of 20 mM Hepes, 1 mM MgCl2 and 2 mM
EGTA (pH 7.2) with a Potter-Elvehjem homogenizer
for 30 s. The homogenate was then stored in an ice-
water bath, to be sonicated an average of 30 min
later. ATPase activity was measured in the same
way as in the rat heart experiments.
2.8. Statistics
The e¡ects of pH and time on F1F0-ATPase activ-
ity in normoxia and ischemia were tested with multi-
ple regression analysis. Analysis of variance for re-
peated measures followed by Student’s t-test for
paired mean values was used when assessing changes
in the activity of F1F0-ATPase at di¡erent pH levels
in the sample preparation and assay. P9 0.05 was
denoted as signi¢cant. Results are expressed as
mean þ S.E.
3. Results
3.1. F1F0-ATPase inhibition in rat myocardium and
isolated mitochondria
The ATPase activity of the sub-mitochondrial
preparations from both normoxic and ischemic
hearts was dependent on the pH of the preparation
and assay medium (Fig. 1). Moreover, inhibition by
ischemia was detectable only at low pH. As shown in
Fig. 2, second-order polynomial regression shows the
pH dependence of the ischemic inhibition to be sig-
ni¢cant at the level of P6 0.001. Multiple linear re-
gression of both the control and ischemic data shows
that the observed activity is dependent on pH
(P6 0.001 for ischemic and controls) but not on
storage time (P = 0.20 for ischemic and P = 0.88 for
controls). It is signi¢cant that although lowering of
pH in sample preparation and assay bu¡ers decreases
the observed activity in both the normoxic and ische-
mic heart, a di¡erence between the normoxic and
ischemic activities can only be shown at low pH
(Fig. 2), being signi¢cant at pH 6.5 (1.53 þ 0.12
(n = 4) vs. 0.55 þ 0.06 (n = 4) Wmol min31 mg31,
P6 0.01), pH 7.0 (1.51 þ 0.14 (n = 4) vs. 1.00 þ 0.10
(n = 4) Wmol min31 mg31, P6 0.05) and pH 7.5
(2.35 þ 0.09 (n = 5) vs. 1.69 þ 0.13 (n = 5) Wmol min31
mg31, P6 0.05, respectively), but vanishing at pH
8.0 (3.39 þ 0.38 (n = 4) vs. 2.82 þ 0.32 (n = 4) Wmol
min31 mg31, not signi¢cant). Thus it is possible to
store the samples for up to 60 min at 0‡C and still
be able to estimate the in situ inhibition state of
F1F0-ATPase reliably, provided that the initial delay
in sample preparation is short and the pH appropri-
ate.
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The inhibition of F1F0-ATPase at 20 min of global
ischemia could be reversed, when the sonicated sam-
ples were incubated 10 min at +25‡C either in pH 9.5
or in 160 mM KCl before assay at pH 7.2. The F1F0-
ATPase activity increased by 3.1 and 2.1 times, re-
spectively (Fig. 3). This indicates that the inhibiting
factor can dissociate from F1F0-ATPase in high pH
or in high salt concentration and this state is stable
at pH 7.2.
The e¡ects of repeated cycles of ischemia are
shown in Fig. 4. A 5-min period of ischemia signi¢-
cantly reduced the F1F0-ATPase activity (2.61 þ 0.02
(n = 4) vs. 2.06 þ 0.14 (n = 6) Wmol min31 mg31,
P6 0.05), but the basal value was restored after a
5-min reperfusion (2.60 þ 0.12 Wmol min31 mg31,
n = 3). After 15 min of reperfusion the F1F0-ATPase
activity was even higher than the baseline value
(3.09 þ 0.06 Wmol min31 mg31, n = 4, P6 0.001 vs.
normoxic value). A 5-min period of ischemia re-
peated after 15 min of reperfusion lowered the
F1F0-ATPase activity signi¢cantly more than the ini-
tial 5 min of ischemia (1.57 þ 0.14 Wmol min31 mg31,
n = 6, P6 0.05 vs. activity after the initial 5 min of
ischemia) (Fig. 3). This augmented inhibition was
lost if the ischemia was repeated after 120 min of
Fig. 3. In vitro release of ischemic inhibition of F1F0-ATPase
by pretreatment with alkaline pH or high [K]. Myocardium
was sampled at 20 min of global ischemia and subjected to
treatments depicted. The curves present typical assays of ATP
hydrolysis measured as NADH oxidation using pyruvate kinase
and lactate dehydrogenase as indicator enzymes.
Fig. 2. pH-dependence of ischemia-induced F1F0-ATPase inhi-
bition observed in the rat heart. Submitochondrial particles
were prepared and stored in a solution at the pH given and as-
sayed immediately. The values are presented as percentages of
the preischemic normoxic activity and given as means þ S.E. for
4^5 hearts. The second-order polynomial regression line is
shown (r = 0.89, P6 0.001).
Fig. 1. E¡ect of storage time and pH of the suspension and
storage medium on F1F0-ATPase activity in samples from nor-
moxic or 20-min ischemic rat hearts. The hearts were processed
as described in Section 2. Open columns, normoxic hearts;
¢lled columns, hearts after 20 min of ischemia. The values are
means for 4^5 hearts, and the error bars depict S.E. Before as-
say, the preparations were stored on an ice bath for the time
indicated. For statistics, see Section 3.
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reperfusion following a 5-min bout of precondition-
ing ischemia (2.16 þ 0.17 Wmol min31 mg31, n = 5)
(Fig. 4). All assays were performed in preparations
produced in 3 min by tissue homogenization with
subsequent sonication and short centrifugation as
described in Section 2.3. However, when the mea-
surements were performed according to Rouslin
and coworkers [4^9], i.e., with a longer procedure
including isolation of mitochondria prior to the assay
there was no di¡erence between the activities after
normoxia (1.88 þ 0.28 Wmol min31 mg31 (n = 3)) and
5-min ischemia (1.85 þ 0.23 Wmol min31 mg31
(n = 3)),.
In isolated mitochondria, uncoupling by CCCP
reduced the F1F0-ATPase activity (3.49 þ 0.07
(n = 7) vs. 3.04 þ 0.21 (n = 5) Wmol min31 mg31
P6 0.05), but this decrease was signi¢cantly greater
in the presence of 5 mM ATP (2.24 þ 0.18 (n = 6)
Wmol min31 mg31, P6 0.05 vs. uncoupling alone,
P6 0.001 vs. normoxia) (Fig. 5).
The dose^response curve of oligomycin inhibition
of state 3 respiration of rat heart mitochondria is
shown in Fig. 6. The control strength was estimated
according to Groen et al. [15] by determining the
initial slope of the curve. In a case of an irreversible
inhibitor (oligomycin) the control strength of F1F0-
ATPase can be calculated from Eq. 1
C  3D J=J0=D I=Im 1
where C is the control strength, J and J0 is the res-
piration in the presence and absence of inhibitor, I is
the concentration of the inhibitor, and Im the mini-
mum concentration of inhibitor su⁄cient for com-
plete inhibition. The minimum amount of oligomycin
needed for full inhibition is determined by extrapo-
lation to the abscissa as depicted in Fig. 6. When
Fig. 6. Dose^response curve for oligomycin inhibition of mito-
chondrial respiration. The mitochondria respiring on glutamate
plus malate were incubated with oligomycin, and the initial rate
of ADP-stimulated respiration was recorded.
Fig. 5. F1F0-ATPase activity in isolated rat heart mitochondria
during normoxia (state 4 mitochondria), uncoupling and uncou-
pling plus 5 mM ATP in the chamber. The ¢lled circles depict
the individual experiments, the open circles are the means and
the vertical bars show þ S.E. The carbonylcyanide m-chlorophe-
nylhydrazine (CCCP) concentration was 2 WM. For statistics,
see Section 3.
Fig. 4. E¡ect of repeated ischemia^reperfusion cycles on F1F0-
ATPase activity in the isolated perfused rat heart. Myocardial
samples were taken at the time points indicated, processed and
assayed as described in Section 2. The values are mean þ S.E
for 3^6 experiments. Two protocols are shown above the time
axis, and the horizontal black bars mark periods of ischemia.
The ¢lled circles refer to values obtained with the upper proto-
col. *The open square refers to values obtained with the lower
protocol. For statistics, see Section 3.
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respiration is presented in relative units and the unit
of abscissa is de¢ned as the amount of oligomycin
required for full inhibition, the slope is equal to C.
The control strength of F1F0-ATPase becomes
0.04 to 0.09 in various mitochondrial preparations.
This means that the observed ischemic inhibition of
F1F0-ATPase would produce a 3^5% inhibition of
phosphorylating cell respiration upon reperfusion.
3.2. Human heart F1F0-ATPase activity
The e¡ects of 5-min ischemia and 7-min reperfu-
sion are presented in Fig. 7 in fractional units with
reference to the preischemic basal values. Five-min
ischemia lowered the F1F0-ATPase activity by
20.3% (from 1.64 þ 0.27 vs. 1.30 þ 0.21, Wmol min31
mg31, (n = 9), P6 0.05), but it returned to the basal
value (1.56 þ 0.24 Wmol min31 mg31) during the sub-
sequent 7-min reperfusion.
4. Discussion
4.1. Nature of F1F0-ATPase inhibition in rat
myocardium
The role and existence of the endogenous mito-
chondrial inhibitors in mammalian heart has been
under intensive discussion for many years. Particu-
larly di¡erent views exist about the existence of the
IF1 inhibitor in fast-beating rodent hearts [3^11]. The
assays have been based on the ability of mitochon-
drial matrix extracts to inhibit ATP hydrolysis in
submitochondrial particles where the ATP synthase
is facing outward [4,6]. No reports exist of an assay
of the rat heart IF1 protein with antibodies raised
against it. It is noteworthy that the enzyme has
been puri¢ed from rat liver [16], and it is a larger
protein than the inhibitor from bovine heart [17].
By de¢nition, ischemic, membrane potential-sensi-
tive and pH-sensitive inhibition of the F1F0-ATPase
must be reversible in intact tissues, thus ruling out
irreversible damage. The reversibility of the inhibi-
tion phenomenon in rat heart is con¢rmed in the
present experiments (Figs. 3 and 4) as has been
done after a longer ischemic period earlier [11]. In
isolated myocytes reversible up and down regulation
of ATPase has been demonstrated by Harris and co-
workers [3,10]. In isolated rat heart mitochondria the
inhibitory e¡ect of uncoupler was small, but this is
appreciable in mitochondria incubated as supple-
mented with 5 mM ATP (Fig. 5). This is in accord
with the ¢nding that ATP hydrolysis is required for
e¡ective inhibition of F1F0-ATPase, as has been
demonstrated in rat liver submitochondrial vesicle
preparation [16]. It is strange that even in intact,
uncoupler-treated rat heart mitochondria extramito-
chondrial ATP is able to enhance inhibition. It has
been shown that ATP is much more e¡ective than
ADP plus Pi in allowing productive inhibition, and
apparently the intramitochondrial ATP is too low
under these conditions.
Thus, there are independent lines of circumstantial
evidence of the existence of a reversible F1F0-ATPase
inhibitor in rat heart. Unless otherwise shown, there
are reasons to regard the inhibition as being due to a
mitochondrial protein behaving like IF1. As demon-
strated in Fig. 3, the ischemic inhibition of F1F0-
ATPase could be reversed by high pH or high KCl
concentration. Both factors are known to dissociate
IF1 from F1F0-ATPase [18,19]. Recently, Cabezon
and coworkers [19] have shown that the pH-depen-
dence of the inhibition of F1F0-ATPase by IF1 is due
to the pH sensitive modulation between inhibiting
tetrameric and non-inhibiting dimeric proteins. The
discrepancy between the observed ATPase inhibition
in rat myocardium and heart mitochondria on one
Fig. 7. Human mitochondrial F1F0-ATPase activity after 5 min
of ischemia and 7 min of reperfusion. The ischemia caused 20%
inhibition (P6 0.001), but this was lost during the reperfusion.
The ¢lled circles are means and the vertical bars show þ S.E.
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hand, and the low titers found in the matrix extract
assay on submitochondrial particles on the other, is
di⁄cult to settle. The a⁄nity of rat heart IF1 for
F1F0-ATPase may be lower than that in other tissues
or species. From the dilute extract of the mitochon-
drial matrix the binding would then be more di⁄cult
to observe than in mitochondria in spite of the fact
that even in assays on mitochondria the inhibition
must survive the breaking and reversion of the inner
membrane by sonication, which indicates that the
detachment of the inhibitor is a slow process.
4.2. Does inhibition of mitochondrial F1F0-ATPase
occur in ischemic preconditioning?
Although the importance of ATP sparing due to
ischemic preconditioning is under dispute [22,28], the
contribution of F1F0-ATPase inhibition is di⁄cult to
rule out. We have previously suggested that ischemic
preconditioning causes more e⁄cient inhibition of
mitochondrial F1F0-ATPase during the ¢rst minutes
of sustained ischemia [11], and similar results have
obtained by Bosetti and coworkers [20]. We origi-
nally thought that this was due to sustained inhibi-
tion of mitochondrial ATPase during the intervening
reperfusion, so that the enzyme is inhibited from the
very beginning of the subsequent prolonged ische-
mia. This could not be corroborated in the present
experiments. On the other hand, when the 5-min is-
chemia was repeated after 15-min reperfusion, inhi-
bition was signi¢cantly greater, even though F1F0-
ATPase activity at the end of the 15-min reperfusion
was higher than the initial normoxic value (Fig. 4),
so that a ‘preconditioning’ e¡ect was seen in F1F0-
ATPase inhibition.
The protection obtained by ischemic precondition-
ing is known to vanish after 30^120 min of reperfu-
sion, depending on the species or the experimental
model used [21]. As shown in Fig. 3, the enhanced
F1F0-ATPase inhibition was lost after 120 min of
reperfusion, supporting the role of F1F0-ATPase in-
hibition in ischemic preconditioning.
Contrary to the ¢ndings by our group and by Bo-
setti et al. [20], neither Green et al. [22] nor Kobara
et al.[23] could detect any signi¢cant di¡erences be-
tween the mitochondrial F1F0-ATPase activities in
sustained ischemia in preconditioned and control
Langendor¡-perfused rat hearts. Both groups mea-
sured myocardial F1F0-ATPase by means of a very
long procedure involving isolation of mitochondria,
which will at least partly explain their negative ¢nd-
ings. In addition, Kobara and coworkers [23] diluted
their sample in the high pH of 9.7, which would
abolish an inhibition by IF1. Anyway, the data pro-
vided by Green and coworkers [22] suggests that is-
chemia inhibits F1F0-ATPase activity by 30%.
Vander Heide and coworkers [24] used mitochon-
dria isolated from dog heart to measure F1F0-ATP-
ase, but performed the isolation and assay at neutral
pH. A negative correlation was found between high
energy phosphate utilization and F1F0-ATPase inhi-
bition, but although the inhibition of F1F0-ATPase
reached a plateau (56% inhibition) in 5 min, the
ATPase activity was the same as in control hearts
after 5 min of reperfusion, even following four 5-
min bouts of ischemia. All this indicates that F1F0-
ATPase inhibition is involved in ATP sparing in the
ischemic dog heart. Unfortunately, Vander Heide
and coworkers [24] did not compare the kinetics of
F1F0-ATPase inhibition during prolonged ischemia
in control and preconditioned hearts, and it is still
possible that in dog myocardium the inhibition de-
velops faster during sustained ischemia after precon-
ditioning.
4.3. Linking F1F0-ATPase inhibition to ischemic
preconditioning and its signi¢cance
A consensus exists that ATP-sensitive potassium
channels play a central role in a protection obtained
by ischemic preconditioning. Several recent studies
have proved, however, that it is not the sarcolemmal
KATP channel but the mitochondrial one that medi-
ates this protection [25^27]. This could also o¡er an
explanation for speeding up the inhibition of F1F0-
ATPase, as the opening of this channel would cause
mitochondrial de-energization and acidi¢cation ow-
ing to H/K exchange, both of which e¡ects would
promote binding of IF1.
Mitochondrial calcium accumulation during ische-
mia occurs through a Ca2 uniporter, which facili-
tates the movement of Ca2 down its electrochemical
gradient into the mitochondrial matrix [29]. As ATP
hydrolysis by F1F0-ATPase strives to maintain the
mitochondrial membrane potential during ischemia,
its inhibition may prevent mitochondrial calcium ac-
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cumulation, as we have recently shown in intact rat
hearts [30]. Reperfusion damage has some character-
istics of the sequels of the mitochondrial permeability
transition (MPT) which occurs upon calcium over-
load, extreme oxidation of NAD(P)H, mitochondrial
de-energization, loss of ATP and oxidative stress (for
a recent review, see [31]). The ATP/ADP translocase
is probably a component of the MPT pore, and ATP
inhibits the opening of the pore triggered by Ca2
and Pi or oxidative stress. Also, mitochondrial cyclo-
philin D is involved in MPT, and the role of the
latter in reperfusion damage emphasized by the pro-
tective e¡ect of cyclosporin A against reperfusion
damage. Since in ischemia ATP hydrolysis to ADP
and Pi leads to both deprotection and MPT activa-
tion, inhibition of F1F0-ATPase should be bene¢cial
and, if e¡ective, should in£uence the conditions just
preceding reperfusion.
4.4. The putative protective role of F1F0-ATPase
inhibition in ischemia
A bene¢cial e¡ect of F1F0-ATPase inhibition is
not self-evident. Most of the ischemic damage ap-
pears upon reperfusion, and although a curb of
ATP waste in ischemia may be protective, an inhibi-
tion of ATP synthase during reperfusion may be
more detrimental than its inhibition is pro¢table dur-
ing ischemia. However, it is easily seen from the data
of Fig. 6, in accord with previous work, that the £ux
control coe⁄cient [32] of F1F0-ATPase is low. More-
over, it must be di¡erent for ATP hydrolysis in is-
chemia and ATP synthesis in normoxia, because the
respiratory chain proper is not involved in the ische-
mic process so that the number of regulative compo-
nents in the opposing pathways is di¡erent. The £ux
of ATP hydrolysis under de-energized conditions and
intact membrane is controlled by the F1F0-ATPase,
ATP/ADP translocator, Pi translocator and proton
conductance of the membrane. In oxidative phos-
phorylation the £ux is principally controlled by the
respiratory chain, F1F0-ATPase, ATP/ADP translo-
cator, Pi translocator, and their substrates.
Although the inhibition by oligomycin is irrevers-
ible, the dose^response curve of oxygen consumption
is near-sigmoidal, as also observed previously [33].
The present results indicate that an oligomycin con-
centration causing 50% inhibition of ATPase, i.e.,
that obtained during ischemia of an intact heart,
causes negligible inhibition of oxygen consumption
(state 3 minus state 4) which is a good estimate of
the oxidative phosphorylation £ux in coupled mito-
chondria. An amount of oligomycin causing 85% in-
hibition of F1F0-ATPase is needed to produce 50%
inhibition of oxygen consumption. These data are in
agreement with the data and model of Korzeniewski
and Mazat [34] for oxidative phosphorylation in
skeletal muscle mitochondria. For ATP synthesis
by oxidative phosphorylation in state 3 they calculate
a £ux control coe⁄cient of 0.18 for F1F0-ATPase, as
compared with 0.24 for complex III, 0.14 for ATP/
ADP translocator and 0.10 for Pi translocator. A low
control strength is also predicted on basis of the
early work suggesting a near-equilibrium across the
¢rst two energy conserving sites of the respiratory
chain and ATP synthase in rat heart [35]. Indeed,
the estimate obtained from the present results from
cardiac mitochondria is close to these values from
skeletal muscle. The respiratory chain is not involved
in ischemic ATP hydrolysis, and much more control
must be exerted by F1F0-ATPase, and this increases
because accumulation of metabolic products prob-
ably increases the proton conductance of the mito-
chondrial inner membrane. Indeed, mitochondria
isolated from ischemic heart show increased rates
of proton leak [36]. An impairment of the adenylate
translocator in ischemia has been found and sug-
gested to be due to inhibition by long-chain acyl-
CoA has been suggested, but as pointed out by La-
Noue and coworkers the latter is unlikely to be the
cause [37]. The F1F0-ATPase inhibition values ob-
served in ischemic myocardium should have only
small e¡ect on oxidative phosphorylation upon re-
perfusion. It is interesting that the F1F0-ATPase ac-
tivity may even increase above the basal value during
reperfusion (Fig. 4). Similar F1F0-ATPase activation
is also seen in the dog myocardium and in cultured
rat cardiomyocytes during increased ATP synthesis
[3,18]. This suggests that even under physiological
conditions some IF1 is bound to the enzyme and
exerts a slight inhibitory e¡ect, allowing an over-
shoot in activity upon reperfusion. That some IF1
is bound to F1F0ATPase even under aerobic condi-
tions is indicated by the ¢nding that lack of IF1
manifest in Luft’s disease characterized by uncoupled
mitochondria, as suggested by the absence of IF1
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from cells cultured from a patient su¡ering from this
disease [38]. Thus IF1 appears to be needed for main-
tenance of proton tightness of the mitochondrial in-
ner membrane. An increase in proton tightness
would also slow the back reaction of the ATP syn-
thase during ischemia and counteract the sequels of
ischemia during reperfusion.
4.5. Clinical relevance of F1F0-ATPase inhibition for
ischemic preconditioning in humans
It has been suggested that ischemic precondition-
ing also occurs in humans [39,40]. Yellon and co-
workers [39] showed in their coronary bypass series
an ATP-saving e¡ect which in principle could be due
to F1F0-ATPase inhibition. In the present case we
observed 20% inhibition of F1F0-ATPase after
5 min of ischemia in human heart. The inhibition
faded rapidly away, and no information could be
obtained of whether its behavior in a subsequent
ischemia is modi¢ed. The protocol was dictated by
the therapeutic surgical procedure and may explain
the extreme transitoriness of the F1F0-ATPase inhi-
bition. First, the aortic root pressure was kept zero
during the 5-min ischemia, so that the work done by
the heart was low and the changes in cellular energy
state small, which may be re£ected in the time course
of the ATPase inhibition. Secondly, upon reperfusion
the hearts were arrested with KCl, allowing the cel-
lular energy state to recover faster. A rapid mito-
chondrial re-energization releases IF1 and the inhibi-
tion of F1F0-ATPase. Thus an inhibition of F1F0-
ATPase can be demonstrated in human heart. The
phenomenon is rapid and volatile, and although it
probably is involved in cell protection, its role in
preconditioning in humans remains open.
We conclude that inhibition of F1F0-ATPase oc-
curs both in rat and human myocardium during is-
chemia. Caution must be exercised with sample prep-
aration and assay conditions in order to demonstrate
a reversible inhibition.
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